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ABSTRACT
The premise of Open Science is that research and medical management will progress faster if data and knowl-
edge are openly shared. The value of Open Science is nowhere more important and appreciated than in the
rare disease (RD) community. Research into RDs has been limited by insufficient patient data and resources, a
paucity of trained disease experts, and lack of therapeutics, leading to long delays in diagnosis and treatment.
These issues can be ameliorated by following the principles and practices of sharing that are intrinsic to Open
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Science. Here, we describe how the RD community has adopted the core pillars of Open Science, adding new
initiatives to promote care and research for RD patients and, ultimately, for all of medicine. We also present rec-
ommendations that can advance Open Science more globally.
Key words: open science, ontology, FAIR data, common data elements, rare disease patients, data standards
INTRODUCTION
In the United States, a rare disease (RD) is defined as one that affects
fewer than 200,000 persons; for Japan, it is fewer than 50,000; and
for South Korea, fewer than 20,000. In contrast, Europe and Austra-
lia define rare as 1 in 2000 individuals.1,2 Taken together, RDs rep-
resent a public health problem; 10% of people eventually present
with an RD.2–4 Roughly 5000–8000 RDs have been described, but
the number of RDs is estimated to exceed 10,000.5 Most RDs are se-
vere and chronic and some are life-threatening. RDs, which are of-
ten inherited, frequently present in childhood and can have
deleterious long-term effects. Patients with RDs often face diagnos-
tic delays; it can take 7 years or more to reach an accurate diagno-
sis.6,7 Delayed or inaccurate diagnoses hinder the development of
effective treatment plans, preclude prognoses and genetic counsel-
ing, create skepticism among relatives, colleagues, and physicians,
and exclude patients from a community of individuals with similar
experiences. Appropriate information and medical expertise on RDs
are often insufficient, and access to care is difficult. Because many
RDs affect multiple organ systems, care can be fragmented across
several specialties. Electronic health records (EHRs) are not well
suited for recording and sharing information about RDs; it remains
difficult to stratify patients into useful classifications and to identify
individuals with specific RDs8,9 (Figure 1).
Programs have been established to accelerate the diagnosis of
very RDs, identify new RDs, and provide improved RD patient care.
One such program was the NIH Undiagnosed Diseases Program
(UDP),10–13 which expanded to the Undiagnosed Disease Network
(UDN). This NIH-funded consortium includes 12 clinical sites and
analytical cores around the United States14,15; both the UDN and
the UDP provide multidisciplinary clinical evaluations, research col-
laborations, and translational validations for RD patients. The
UDN uses many hundreds of open data resources that have helped
inform many diagnoses, illustrating the success of Open Science for
diagnosing RD patients. Similar RD diagnostic initiatives in other
countries have been instantiated in Japan in 2015 (Initiative on Rare
and Undiagnosed Disease [IRUD]16) in Western Australia in 2013
(Rare and Undiagnosed Diseases Diagnostic Service, RUDDS), and
in other countries. The Undiagnosed Diseases Network Interna-
tional (UDNI), established in 2014, is dedicated to discovering new
diseases and defining standards for sharing data and best practices
in RD programs throughout the world.11 With the Cross-Border
Healthcare Directive (2011/24/EU), the European Union established
a mandatory framework to foster cooperation addressed to RDs
within European Reference Networks.17 Despite these laudatory
efforts to coordinate internationally, there are not enough programs
worldwide to provide the care needed for the many RDs patients. In
addition, RD patients often lack a supporting community that
shares the same disease, despite the many support groups such as the
National Organization for Rare Disorders (NORD), European Or-
ganization for Rare Diseases (EURORDIS), and Coordination of
Rare Diseases at Sanford (CoRDS).
OPEN SCIENCE AND MAKING DATA FAIR
Individually, RDs are rare, and so any one physician, researcher, or
institution will not accrue sufficient experience, data, or knowledge
to effectively treat or research RDs. Therefore, progress in diagnos-
ing, treating, and understanding a particular RD requires the synthe-
sis of all available data from multiple institutions.
To facilitate this exchange of data, the field has started to em-
brace the principles of Open Science. The premise of Open Science is
that research will progress faster if data and knowledge are openly
shared with proper data safety measures and ethical frameworks.18
Open Science, an umbrella term for a wide range of activities from
basic biological research to clinical research, makes it easier for sci-
entists and clinicians to share and access knowledge, resources,
tools, and data. Open Science considers scientific knowledge a prod-
uct of social collaboration that belongs to the community; hence,
the public should have access to it at little or no cost.
Lay summary
Open Science refers to the practice of openly sharing scientific resources (eg, publications, data, findings, knowledge, soft-
ware) and making them accessible to the general public, including lay people as well as professionals By enabling access to
information from a range of sources, specialties, and geographical locations, Open Science can accelerate our understand-
ing of the underlying causes of diseases, helping to reduce the time needed to develop new treatments and thereby improve
the quality of life for all people.
There are thousands of rare diseases (RDs), each one affecting relatively few people. Cumulatively, RDs affect millions
across the globe, but because each disease is so rare, an individual doctor or researcher may encounter very few patients
with the condition. RD research can therefore particularly benefit from data sharing, which is a pillar of Open Science. Rec-
ognizing the potential for a faster path to diagnosis and treatment, many RD patients and their families have been eager to
share their data despite privacy challenges. In this article, we address some of the important developments, resources, and
technologies that have been initiated and/or utilized by the RD community, along with a set of recommendations for advanc-
ing Open Science. The RD community—patients, advocates, physicians, and scientists—has led the way toward openness,
collaboration, and data sharing, demonstrating that they are thought leaders in Open Science.
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In a very real sense, Open Science means open data. To be open,
the data need to be FAIR, that is, Findable, Accessible, Interopera-
ble, and Reusable (FAIR) for humans and machines.19 These FAIR
Guiding Principles,20 adopted in 2014, are followed by many organ-
izations world-wide, including the G20, NIH, and IRDiRC (the In-
ternational Rare Disease Research Consortium). Many projects,
such as the European Joint Programme on Rare Diseases, are now
working on the implementation of FAIR. Germany, France, and The
Netherlands decided to support communities in organizing Global
Open FAIR implementation networks. The RDs GO FAIR Network
was established to foster implementation in the RD domain.21 Also
important are factors specifically related to data reusability, such as
traceability (eg, provenance and attribution), data licensing, and
connectedness of the data.22–24
FAIR data stewardship is challenging, because it requires a wide
range of expertise: knowledge of the domain, local IT systems, local
and cloud storage systems, local and global data access policies,
machine-readable formats for data and knowledge, and software for
communication between FAIR resources. Making data FAIR should
be considered a team effort. There is no comprehensive suite of tools
for a stakeholder to make data FAIR; ELIXIR’s “service bundles”
may provide that in the future, but teams of experts are needed.
The FAIR principles require data to be prepared for reuse. More-
over, for diseases with low prevalence, sparsity of data necessitates
that data are prepared for analysis across multiple sources. Current
lack of interoperability is an obstacle for Open Science.25 Data sci-
entists must go through a laborious and error-prone process of find-
ing data, assuring access and permissions, and making data
compatible and optimally reusable. By experience, this post hoc
data preparation may take up a substantial part of their time,26 and
inevitably leads to an inability to address certain research questions.
Open Science needs international collaboration, infrastructure, and
good data stewardship to address the costly inefficiency caused by
data that are not prepared for reuse.
Sharing data can be problematic in general, but particularly in
the RD domain, because of (1) ethical and legal constraints that can
differ among institutes, regions, and countries, (2) the scale of the
distribution of RD data, and (3) hesitation of scientists to share data
that are precious to their careers. The FAIR principles can provide
an alternative approach to centralizing data, especially clinical data,
from multiple sources for analysis. When data are FAIR “at source,”
distributed analysis can be effectively performed, with only the re-
sult of the analysis leaving the source and the data secure and pri-
vate. In principle, all source data are available, enabling analyses
ranging from counting how many patients show certain conditions
to distributed machine learning to predict treatment outcomes.
Some computer algorithms will be too demanding for distributed
analysis, but even in that case, application of the FAIR principles
will prepare data for efficient analyses.
Another significant challenge is data licensing. Integrative ana-
lytical platforms aimed at facilitating RD research and mechanism
and drug discovery, such as the Monarch Initiative,27 the NCATS
Biomedical Data Translator,28–30 and the Gabriella Miller Kids First
Data Resource Portal,31 rely on the ability to integrate and redistrib-
ute data from other third-party public knowledge sources. The more
FAIR-ready these sources are, the more the integrated data may be
effectively applied for RDs. However, a recent study evaluating
more than 50 data sources suggested that current licensing terms
may significantly impede the use, reuse, and redistribution of data.
The lack of legal data redistribution is a fundamental problem for
RDs, for which maximal utility must be garnered from all possible
knowledge sources. Custom licenses constitute the largest single
class of licenses found in these data resources, suggesting that the
providers either did not know about standard licenses or believed
that standard licenses did not meet their needs.22,23 The (Re)usable
Data Project32 aims to help data providers evaluate the impact of
their licensing terms on downstream users, and is already assisting
RD data providers to improve their reusability.
Despite these challenges, the benefits of FAIR outweigh the cost of
implementation. Theoretically, the additional time to make data com-
patible for multi-source analysis by a data analyst is zero when data
are already FAIR.33 Considering that RD data sets are precious and
(a) (b)
Figure 1. Rare diseases. (A) RDs are individually rare but collectively impact 10% of the population. Here, RDs are represented in the classic aphorism, “When
you hear hoofbeats, think of horses, not zebras”—in other words, look for the most common disease that matches the symptoms, not the rarest one. It was origi-
nally used by Theodore Woodward, professor at the University of Maryland School of Medicine in the 1940s. (B) Defining RDs requires carefully matching a
patient’s spectrum of phenotypes with the phenotypic profile of candidate diseases, here represented by a single color-feature. Each zebra (patient) has a constel-
lation of phenotypes that may match none, some (dashed lines), or all (solid lines) of the phenotypes of other zebras. The diagnosis of RDs often involves recogni-
tion of phenotypic patterns and is aided by computational phenotype analysis.
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reused often, the efficiency gain multiplies quickly. The RD commu-
nity was the first community in Europe to embrace the concept of a
“Bring Your Own Data” workshop (BYOD) aimed at learning how
to make data interoperable. BYODs for RD registry managers have
been organized by the Istituto Superiore di Sanita since 2015,34 and
are planned to continue as part of an annual summer school at least
until 2023 with support from the European Joint Program on Rare
Diseases (EJPRD). Inspired by the feedback from these BYODs, “RDs
GO FAIR” was created to foster adoption of FAIR principles toward
a critical mass of FAIR data resources.17 Through interdisciplinary
collaboration fostered by RDs GO FAIR and others, and activities of
ELIXIR, BBMRI (Better Biology Makes Reality Interesting), the NIH,
the EJPRD, NORD, and EURORDIS, we expect gradual maturation
of guidelines, supporting tools, FAIR data stewardship (including in
patient organizations), and for-profit and not-for-profit service pro-
viders. A FAIR ecosystem thus brings about an Open Science environ-
ment where new analysis possibilities can be explored under well-
defined and transparent conditions for sensitive data.
OPEN SCIENCE IN THE RARE DISEASE FIELD
RD patient empowerment and resources
Patients, families, and their advocates are key stakeholders that have
not always been sufficiently engaged in many biomedical research
initiatives.35 Engaging patients as partners in product development
is important to better understand the patient perspectives and the
pathogenesis of the disease. Patients and caregivers are often the
best advocates for raising awareness and describing the clinical man-
ifestations and the daily progress of the disease and treatments.36
Engagement of patients and other stakeholders (such as caregivers,
advocacy organizations, and clinicians) in clinical research can help
to ensure that research efforts address relevant clinical questions and
patient-centered health outcomes.37 Numerous RD programs and
organizations exist, including the NIH Rare Disease Clinical Re-
search Network (RDCRN),38 the EURORDIS-Rare Diseases Eu-
rope,39 Patient-Centered Outcomes Research Institute (PCORI),40
the Genetic Alliance,41 NORD,42 and the Innovative Medicine Ini-
tiative (IMI).43
Many patients and their families look for ways to improve dissem-
ination of their data and help catalyze research in their RD in a hope
for faster and better diagnosis and treatment. There are many inspir-
ing examples of individual patient or a parent who with little resour-
ces but with much determination, they established a foundation for
their RD, shared their data and created a successful collaboration be-
tween scientific researchers and patient organizations. A few to men-
tion are: Syndromes Without A Name USA (SWAN),44–47 Ngly1.org
foundation,48,49 the Chordoma Foundation,50 the Castleman Disease
Collaborative Network,51 the Joshua Frase Foundation,52 the Cystic
Fibrosis Foundation,53 and the PXE International.54 In all of these
cases, there has been not only a patient or parent creating research
programs and collaborations but also data sharing and data reutiliza-
tion to support diagnosis and discovery. These foundational patient-
scientist collaborations are a clear window into what will become the
de facto standard, that is, Open Science, international collaborations
involving patients, clinicians, researchers, and data technologists in a
global venue.
The diversity of the aforementioned activities has contributed to
the mention of the importance of patient engagement in RD clinical
trials in the US Food and Drug Administration (FDA)’s 2019 draft
guidance document for industry.35 The role of patients’ and parents’
support groups is growing beyond the boundaries of individual na-
tional initiatives aimed at raising public awareness and promoting
medical care and social benefits.
Common data elements
Open access to data is not sufficient to make the data useful to sci-
ence; data must also be structured, documented, interoperable, and
curated. The magnitude of this task has led to the development of
programs and software that helps automate data curation, data inte-
gration, and data mining; it has also underscored the need for ma-
chine learning and language processing.8,55–58 Health data comes
from many different sources, and many different people produce,
curate, and use the data. Integration is obstructed when systems and
studies use different words to describe the same objects or concepts,
use the same words intending different meanings, or use different
data formats or structures.
Common data elements (CDEs) are a universal language that
describes the data collected in a study. CDEs make data meaningful by
structuring and defining commonly used, community shaped, recom-
mended measures, and assessment instruments. Using CDEs when first
collecting biomedical data makes it easier to develop meaningful analyses
and research projects. When data is associated with CDEs, they can be
more readily analyzed and reused to accelerate research into disease path-
ogenesis and therapeutic development. Although some CDEs were origi-
nally developed to address the needs of a specific research domain or
clinical application, many CDEs address universal concepts of interest to
a wide variety of domains for a variety of data collection purposes, such
as demographic characteristics of research participants. In many cases,
CDEs related to RDs may be broadly applicable for collecting data about
other diseases, or for rapidly pivoting to collecting well-defined data criti-
cal for research related to emerging diseases, such as lung function meas-
ures that might have been developed for people with cystic fibrosis, and
might be leveraged for use with patients with COVID-19. Identifying and
reusing existing CDEs paves the way for smoothly finding, interpreting,
and exchanging data. Unambiguous definitions are critical. For compara-
bility among sources, CDEs should describe not only the data to be col-
lected, but also rich metadata, that is the manner in which the data are
collected and how the data are recorded. CDEs should define the parame-
ter space for the data point and, instead of using natural language, they
should encourage the use of standardized terminologies and ontologies.
While consistency of data collection and the use of CDEs within an indi-
vidual study are essential for maintaining data quality and enabling analy-
sis, consistency of data collection across multiple studies brings additional
value by promoting data sharing.59
Nevertheless, despite potential benefits and the extensive use of
CDEs across clinical research studies, there are some challenges.
There may be differences across studies in the interpretation and im-
plementation of the data elements; researchers must ensure that
CDEs are valid in different populations recruited for a study (eg,
participants may have different cultural and linguistic backgrounds).
Adoption of CDEs can be inhibited by existing research practices
and legacy data systems. Conversely, use of clinical research data be-
yond the original purpose for which it was collected requires that
researchers ensure that the collected data and its use is consistent
with the informed consent and research ethics.
Data collection and annotation with a well-defined, controlled
vocabulary and terms allow describing the meaning of data in a hu-
man and machine-readable way, enable data harmonization and
meta-analyses, and enhance data sharing. Lack of standardization
hinders data sharing and interoperability, so the use of CDEs is par-
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ticularly critical for research and clinical care for people with RDs.
The National Institutes of Health (NIH) Common Data Element Re-
pository (CDE-R), developed and hosted by the US National Library
of Medicine (NLM), is a platform for identifying related data ele-
ments in use across diverse areas, for harmonizing data elements,
and for linking CDEs to other existing standards and terminolo-
gies.60,61 NLM and others across NIH work to ensure that formal
vocabularies used to describe people, health problems, and health
care processes are sufficiently robust to encompass the full range of
health and disease across all populations and all communities.62–75
The CDE-R contains many CDEs developed for and by the RD re-
search community, the Global Rare Diseases Registry Data Reposi-
tory (GRDR).76,77 The PhenX toolkit is a catalog of measurement
protocols, developed with a robust community consensus proto-
col.78 PhenX notes that its protocols can be used to combine studies
to increase statistical power, enable comparisons of studies to vali-
date results, and increase the impact of individual studies. PhenX
has been used for the application of standardized measures in many
clinical research studies, many of which are submitted to dbGaP.
PhenX contains a collection of measures for Rare Genetic Condi-
tions79 that, while very useful, would require significant expansion
beyond their current remit of 10 per domain to be relevant to the
10 000 RDs that exist. PhenX also allows the creation of clinical
data collection forms in standardized tools such as REDCap,80
which prospectively is a great advantage in standardizing data. All
of the aforementioned efforts help support improved interoperabil-
ity of clinical data across studies; they are critically important for
RDs, for which data from one study or a different RD may help in-
form others.
Many RDs lack consistent identifiable terms, limiting literature
searches, registry interoperability, and comparability in clinical infor-
mation systems. Despite the advances in the creation of CDEs, many
RDs lack a comprehensive set of disease definitions, associated pheno-
types, genetic variations, treatments, prognoses, and other disease
characteristics. However, CDE-development efforts that involve mul-
tidisciplinary collaboration, including informatics expertise, can ad-
dress some of these challenges by identifying synonymy, clearly
defining terms, and achieving consensus of key stakeholders for adop-
tion of the CDEs. For example, this process was used to develop
CDEs and guidance for health information exchange of newborn
screening orders and results for lysosomal storage disorders. We now
detail ongoing efforts to address this gap; the next steps would be to
implement such components into CDEs, clinical systems such as
EHRs, clinical decision support tools, and RD registries.
Data collected for RD research typically includes laboratory
measurements, clinical observations, imaging, genomics and other
’omics data, as well as patient-reported outcomes (PROs). However,
one of the biggest challenges for RD diagnosis is that RDs are not
well-represented in terminologies typically used within EHRs, diag-
nostic settings, or other clinical information systems. The aforemen-
tioned CDEs for RD are intended to address this issue, but
standardized ontologies are still lacking for use in those CDEs and
clinical systems. Ontologies provide precise definitions of terms and
relationships between different terms, which makes it possible to
provide better quality checks, remove ambiguity, and provide much
greater computability and utility in diagnostic or other algorithms.
Precision medicine would greatly benefit from improved logical rep-
resentation of clinical terminologies for classifying patients9; simply
put, RD diagnostics requires it.
The Human Phenotype Ontology
The Human Phenotype Ontology (HPO) provides a structured, com-
prehensive, and well-defined set of terms that describe phenotypic
abnormalities seen in human disease. It also provides a collection of
disease-phenotype annotations, that is, computational assertions
that a disease is associated with a given phenotypic abnormality.
The HPO was created to enable “deep phenotyping,” that is, cap-
ture of symptoms and phenotypic findings using a logically con-
structed hierarchy of phenotypic terms.81,82 The HPO is a flagship
project of the Monarch Initiative, an international consortium dedi-
cated to developing integrative semantic technologies for disease di-
agnosis and mechanism discovery.27,83–85 The HPO allows
algorithms to match sets of patient phenotype profiles in a “fuzzy”
non-exact manner to gold standard RD profiles, other patients, and
model organisms, greatly facilitating diagnosis.86–88 The HPO has
therefore become the de facto standard for representing clinical phe-
notype data for diagnosis for rare genetic diseases by the 100 000
Genomes Project,89 the UDP,13,90 and Undiagnosed Diseases Net-
work (UDN), as well as thousands of other clinics, laboratories,
tools, and databases59,91,92; it is also a IRDiRC (International Rare
Diseases Research Consortium) Recognized Resource.93
Although the focus of the HPO has, to date, been on RDs, it has
been extended to provide a computational foundation for
phenotype-driven analysis of genomes and other translational re-
search on complex human disease.91 For example, many of the labo-
ratory data recorded in EHRs for RD patients are expressed in an
exact manner, such as measurements captured using the Logical Ob-
servation Identifiers Names and Codes (LOINC) standard for identi-
fying medical laboratory observations. Recent efforts have been
made to support interoperability between HPO and LOINC, such
that direct measurements can be converted into HPO codes and
used for diagnostic purposes.94
Deep phenotyping can be time-consuming and may miss key
phenotypic features because they are not assessed (eg, phenotypes in
internal organs that are only observable if a CT is performed) or not
reported (eg, an inconsolable child or heavy snoring may not be
documented in a clinical setting). Patients could therefore provide
informative contributions to their computable phenotype profiles;
however, the “terminology gap” between medical professionals and
patients can limit patient participation both in research studies and
in clinical phenotyping. Current patient vocabularies provide broad
consumer equivalents for clinical findings, medical procedures and
equipment but are not well integrated with research terminologies.
For undiagnosed patients and those with RDs, affected individuals
themselves are an especially critical source of phenotyping informa-
tion. These patients accumulate a clear, firsthand knowledge about
their condition, first from observing how the condition progresses
daily, but also from multiple clinician evaluations and from other
families and patients with similar conditions. In some cases,
patients’ self-phenotyping combined with additional investigations
has led to clinical diagnoses.95
To address these issues, the HPO was further developed to allow
capture of patient-generated phenotypic profiles for use in diagnos-
tic and patient community settings (registries, forums, clinics, and
patient websites). To achieve this, a patient-centered lexicon of rele-
vant terms was developed and added to the HPO.59,91,92 These
terms are frequently referred to in plain language but can also in-
clude clinical terms (eg, Myopia [HP: 0000545] has a lay synonym
“Near-sightedness”). Since the lay translation of the HPO uses the
same logical infrastructure as the HPO itself, patient-generated phe-
notyping data can be readily combined with clinical phenotyping
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data to prioritize variants, improve diagnostic rates, and examine
expressivity, penetrance and disease progression. Formal evaluation
of the diagnostic capabilities of the lay HPO is in progress, and
includes an informatics comparison against the gold-standard HPO
disease annotations used in genomic diagnostics for patients with
RDs. The lay HPO is expected to serve as a resource that will allow
patients and families to become more effective partners in transla-
tional research, empowering families to achieve an accurate diagno-
sis and enabling people to improve the lives of others with RDs by
increasing medical knowledge through their personal perspectives.
The lay HPO should also enable RD patients to share their pheno-
typing profiles openly on the web using standards such as Pheno-
packets (see below), which allows the use of informatics to support
open querying for similar patients to improve diagnosis.
Databases to share rare disease knowledge
While the HPO81 has become a global ontological standard for rep-
resenting phenotypic attributes of RDs, community coordination of
RD disease terminology is still emerging. Different terminological
and database resources have been developed that describe RDs. The
Online Mendelian Inheritance in Man (OMIM) began in the early
1960s by Dr. Victor A. McKusick as a catalog of Mendelian traits
and disorders and has since become a global standard for documen-
tation of Mendelian diseases.96,97 OMIM provides highly curated
knowledge on genes and genetic diseases, phenotypes, and the rela-
tionships between them. Each disease listed in OMIM has a current
summary of information based on expert review of the biomedical
literature. Orphanet was established in France by the INSERM
(French National Institute for Health and Medical Research) in
1997, and provides the community information and nomenclature
on RDs; it is focused on improving the visibility of RDs in health
and research information systems, particularly in Europe. The
ORDO98 Orphanet rare disease terminology, an IRDiRC Recog-
nized Resource,93 has been successfully used in the RD-Connect
Sample Catalogue,99,100 which is an open data repository with infor-
mation about biological samples from RD patients that are available
to scientists for (re-)use. Disease infoSearch (diseaseinfosearch.org)
is a crowdsourced database of thousands of diseases that helps
patients find resources and studies, and integrates information from
numerous sources, such as the NIH Genetic and Rare Diseases Infor-
mation Center (https://rarediseases.info.nih.gov/). These RD-
spanning databases are complemented by gene-, disease-, and/or
locus-specific databases. For example, both the Human Genome
Variation Society (HGVS)101 and the Leiden Open Variation Data-
base (LOVD) list approximately 1500 expert-curated locus-specific
mutation databases.102
Approaches to discovering the genetic basis of disease include
linkage studies, genome-wide association studies, and a variety of
designs involving next-generation sequencing including whole-
exome and whole-genome sequencing. The majority of software
used for these analyses are open access, greatly facilitating the pace
of discovery. The results of many studies are also readily available.
For example, the National Human Genome Research Institute
(NHGRI)-EBI GWAS catalog reports over 70,000 variant-trait asso-
ciations from >5000 studies.103 GenBank has freely released DNA
sequence data since 1982.104 ClinVar is a public archive of reports
of the relationships among human variations and phenotypes, with
supporting evidence.105 The Genome Aggregation Database (gno-
mAD) is an aggregation and harmonization of exome and genome
sequencing data from a variety of large-scale sequencing projects.
Summary data are available for the wider scientific community
based on genomic sequences of over 140,000 individuals. Also, the
Database of Genotypes and Phenotypes (dbGaP) at NIH and the Eu-
ropean Genome-phenome Archive (EGA) at EBI.106 These are exam-
ples of resources that are facilitating major progress in the discovery
of genes and their functional characterization, leading to progress
toward improved diagnosis and treatment.
Recently, major knowledge sources on RDs such as Orphanet,
OMIM, ClinGen, MedGen, GARD, NCI Thesaurus, and others
have been working together to harmonize disease definitions in a
new ontology called “Mondo”,107,108 meaning “world”. While
Mondo is still in development, the new ontology already provides a
computational framework for defining RDs based upon logical rep-
resentation of a variety of attributes such as phenotypes, genetic var-
iants, treatment, onset, frequency, etc. Algorithmic and manual
curation efforts have been used to align these RD terminologies,
yielding preliminary estimates that the total number of RDs may ex-
ceed 10,000, that is, many more than the 7000 estimated during
the inception of the Orphan Drug Act.109 More than half of these
RDs can be found in three or more resources, whereas 4 K are
unique to a given source. This preliminary analysis suggests that
there could be a substantially higher number of RDs than currently
assumed, with obvious implications for diagnostics, drug discovery
and treatment. However, it should be emphasized that much more
rigorous analysis is needed to establish the accuracy of this estimate.
Because RD patient presentations are heterogeneous and may
not perfectly match existing disease definitions based on very small
populations, it is critically important to share patients’ phenotypic
information to support diagnosis, matchmaking, patient registries,
communities, and target drug development. Further, despite the sub-
stantial improvements in exome analysis that have revealed numer-
ous new rare Mendelian disease genes, the specific causal gene
cannot be identified for more than half of patients.109 For these
patients, evidence for causality depends on identifying other affected
individuals with a similar phenotype and functionally impactful var-
iants in the same candidate gene. In order to support this n-of-1 pa-
tient matching, the Global Alliance for Genomics and Health
(GA4GH) initiated the Matchmaker Exchange (MME).110 MME is
a federated network connecting different patient databases contain-
ing genomic and phenotypic data using a common application pro-
gramming interface and allowing data exchange among them. MME
has helped diagnose thousands of patients globally, by connecting
these regional resources in a data sharing network that preserves pri-
vacy and maintains clinical review of potential matches and subse-
quent diagnoses.
While the MME has significantly advanced diagnostic potential
for very RD patients, it does depend upon a patient being registered
within a participating MME database. To increase computability of
the phenotype data and to maximize potential open data sharing of
patient phenotype information, the GA4GH created Phenopackets.
Phenopackets is a standard file format for sharing phenotypic infor-
mation that enables structured data sharing of information about a
participant’s phenotype, such as clinical diagnosis, age of onset,
results from lab tests, and disease severity.111 It can link to separate
files containing a patient’s genetic sequence and pedigree, if avail-
able. Phenopackets are expected to standardize phenotypic data ex-
change within medical and scientific settings. This will allow
phenotypic data to flow among clinics, databases, clinical labs, jour-
nals, and patient registries in ways that are currently feasible only
for more quantifiable data, like sequence data. As more Phenopack-
ets for RD patients are shared, clinicians, biologists, RD registries,
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and disease and drug researchers will build more complete models
of disease and match similar patients (Figure 2). In addition, the use
of Phenopackets to better represent and share the heterogeneity of
RD presentation will lend itself well to drug repurposing. However,
repurposing drugs similarly relies on sharing knowledge that has al-
ready been generated but may otherwise be difficult to access for
those trying to repurpose.112 Monarch’s RD diagnosis tool Exom-
iser113,114 now takes Phenopackets as input, and Phenopackets are
being adopted for projects such as the Japanese Agency for Medical
Research and Development’s BioBank Network (biobank-search.-
megabank.tohoku.ac.jp) as well as SOLVE-RD (solve-rd.eu), the
RD project of the European Commission.
RD registries
Registries are considered key instruments for developing RD clinical
research, enhancing patient care and health planning, and improving
social, economic, and quality-of-life outcomes115,116 for the analysis
of the natural history of RDs.117 Traditionally, registries have been
either population-based or hospital-based. The former aim to cap-
ture all cases from a specific population and are focused on incident
cases, seeking to describe the natural history of diseases.118 The lat-
ter provide responses to different clinical questions, serving as a
source of patients for clinical trials and identifying and analyzing
biomarkers as clinical prognosis factors.119 Both strategies are valid
and are complementary because each can control for different types
of biases.
Defining a standardized set of data elements is a key function
and a key challenge for all registries120; the process of standardiza-
tion is closely linked to the original sources of information used. The
primary source of information is the patient and/or the physician
collecting information directly from the patient; these sources have
been used for centuries. However, standardizing the phenotype is
not simple because we want the data collected to represent the
patient’s clinical course. Standards such as CDEs, PROs,121 and
ontologies such as HPO82 are not used by most registries; those that
use them often do so in an ad hoc manner. Therefore, the main chal-
lenge for capture and reuse of registry data is transforming the
physician’s free text or bespoke encoding into a standardized form.
Specifically, how can the reliability between observers and within
observers be guaranteed in an RD registry.122 Is the phenotype col-
lected at a single point enough to define the full natural history of
the disease? How long should be the follow-up period for each spe-
cific RD? How can a registry help in the analysis of natural and tem-
poral variability of diseases? In fact, the only way to provide valid
health outcomes is to guarantee the quality of all procedures in-
cluded in the registry123; the use of ontologies instead of classical
registry-specific standardization provides added value. Such stan-
dardization uses strict definitions, controls all parameters for each
data element, and provides a high level of certainty about the data
already collected and saved. Conversely, ontologies allow clinicians
a certain level of confidentiality and flexibility because the terms are
probabilistically linked. Ontologies and related standards facilitate
data sharing among registries and improve interoperability between
clinical and research systems.
Other secondary sources of information such as EHRs124 can
provide some structured information are usually well standardized.
EHRs can provide some information for certain types of registries,
but since they have been built for other purposes with different crite-
ria, they are not always appropriate for the aims of registries (EHRs
typically contain a problem list functionality, while standardized
and structured capture of symptoms is almost never available). RD
registries have the capacity to reveal new disease genes, modifier
variants, and new or very rare phenotypes, as well as the assessment
of biomarkers, new treatments, and the impact of the implementa-
tion of health measurements. However, maximizing a registry’s abil-
ity to address unmet needs of RD patients requires data sharing and
phenotypic and omics data, by researchers. Well designed and man-
aged registries are regularly used for these purposes, but they must
adapt their methods by collecting data directly from the EHR to
identify the phenotypes instead of searching and recording specific
data elements.
At early stages of registry planning, patient groups can provide
support both as advisors and as partners. Patient groups can propose
the creation of registries to healthcare institutions and work in a
partnership. These outstanding, emerging possibilities should be
carefully considered.125 As a recent example, several patient associa-
tions have contacted the Italian National Health Institute to estab-
lish and maintain disease-specific registries, and formal agreements
have been signed between each association and the Institute. Fur-
ther, the use of standardized registry software such as NORD’s Nat-
ural Histories Patient Registry Platform, RDconnect’s Registry
Finder126 Coordination of Rare Diseases at Sanford (CoRDS), and
the Program for Engaging Everyone Responsibly (PEER), are all
examples of improved interoperability and data sharing and evolu-
tion with the standards over time. Ideally, such platforms will even-
CURRENTLY WITH PHENOPACKETS... IN THE FUTURE ...
Phenopackets provides a format for integrating 
an individual's genomic data and phenotypic 
information that can be used for electronic data 
exchange.
Phenopackets will enable a whole network of 
phenotypic data exchange that improves our 
ability to understand, diagnose, and treat 
diseases.
Many healthcare systems still rely on manual 
entry of phenotypic data, making it difficult to 
exchange information electronically in a 
standard way.
Figure 2. Phenopackets provide a mechanism for structured, de-identified, patient-level phenotype data sharing for computational use across the globe and in dif-
ferent information systems. Image credit: GA4GH Communications Team.
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tually robustly support both patient-generated individual content
and synchronization with EHR data—something that is likely to im-
prove clinical trial efficacy, recruitment, and engagement.
In general, early engagement of patient groups can substantially
contribute to the success of the registry. The patient’s general contri-
bution will assure that the Registry meets the patient’s needs and
priorities, as well as their own data sharing wishes More specifically,
patient engagement supports recruitment, relevance to patient
healthcare, and the transparency of the process.127 Nevertheless, ro-
bust guidance on this issue is still insufficient and approaches to
meet the challenge should be refined. Methods of engagement may
vary based on the registry’s aim and many other factors. However,
direct participation of the Registry governance at several levels is
suitable for engaging patient partners in decision-making. Patient
engagement in registries is an evolving field that presents both op-
portunities and challenges. Early engagement in the planning phase,
consistent engagement throughout the registry functioning, rele-
vance to patient needs, empowerment of each team component as
well as transparency will create a tool that will both serve the
patients and society and provide novel and integrated know-how.
Simply put, RD registries are key to maximizing data sharing, pa-
tient communication across the globe for RD communities, delineat-
ing disease mechanisms, and promoting drug discovery; however,
they are challenged in interoperability, maintenance, multi-model
data types and sources, and governance.
Facial imaging, an artificial intelligence technology for
RD research and diagnostics
The ability of artificial intelligence (AI) technologies to integrate and
analyze data from different sources can be used to overcome some
of the RDs’ challenges.128,129 In recent years, there have been signifi-
cant advances in disease diagnosis as a result of new technologies for
collecting and analyzing data. Researchers and clinicians are using
these technologies to diagnose rare genetic diseases by scanning a
person’s face or a photograph. AI can also be applied to speech
structure and patient movement.129
The eagerness of the RD patients and their advocates to share
their data and collaborate, despite the many privacy concerns, has
facilitated the implementation of state of the art technologies in di-
agnosis and improving quality of life. Such new technologies include
the ability to diagnose rare genetic diseases by scanning a person’s
face or a photograph. Many RDs are manifested in a distinctive and
recognizable facial phenotype, such as Noonan syndrome and Cor-
nelia de Lange syndrome.130,131 Algorithms that analyze facial
images have matured in recent years so that they predict several hun-
dred RDs with a high degree of accuracy.20 Three-dimensional facial
analysis (3DFA), an evolving deep phenotyping application, pro-
vides detailed representation and analysis of the RD phenotypes that
can generate biological insights. In the RD domain, 3DFA is increas-
ingly being implemented primarily for diagnostic purposes132–134
but also for monitoring existing and trial therapies.133,135,136
Advanced facial analysis platforms such as Cliniface,137 FACE2-
GENE,138 FaceBase,139 and DeepGestalt130 can point doctors in the
direction of specific disorders or genes that could be responsible for
the patient’s symptoms, potentially reducing the number of diagnos-
tic tests needed to confirm the diagnosis. Facial analysis can also of-
fer greater diagnostic certainty when the genetic causation remains
undetermined or when molecular testing is unavailable, for example,
in resource poor environments. AI and other analytic approaches
provide objective analysis of phenotypes and the association of
phenotype and genotype to streamline diagnostics, including ge-
nomic sequence interpretation.129,140 The application of facial
analysis to RD diagnosis and care will require open source
approaches as well as platforms that facilitate pre-competitive
tools and partnerships, and that can be integrated with multi-
omics initiatives.
An example is the Cliniface 3D facial analysis platform.137 Clini-
face 3D tools have been shared for integration in multi-omics plat-
forms for RD research, including through the Personalized Medicine
Center for Children at the Telethon Kids Institute, and it is being
prepared for partnership with the National Rare Diseases Registry
System of China.141 Cliniface has been implemented across multiple
research and clinical environments, including state-wide for the
Western Australian Health Department, and is being increasingly in-
tegrated with the Patient Archive knowledge management plat-
form142 which is connected to MME.110 Cliniface converts 3D
facial images to text-based descriptions, specifically HPO terms.
Converting face-to-text reduces the risk of individual identification,
mitigating against the inherently identifying nature of facial data.
These text-based descriptions can be shared through MME or
Phenopackets, and they can be incorporated into text-based diag-
nostic support algorithms.
One of the most promising resources for facial data sharing is
the Minerva Initiative.143 While it was originally launched for 2-D
data sharing, the underlying principles are intentionally extensible
to 3-D data. The initiative includes a research data resource (Mi-
nerva Image Resource—MIR) and an open research consortium
(Minerva Consortium—MC) which allows the sharing of identifi-
able patient data, such as facial photographs and collaborative re-
search projects on RD. It operates in the spirit of Open Science to
enable precision public health. The Minerva Initiative has the fol-
lowing objectives: to build a community of researchers and clini-
cians, to continue to develop ethical structures and provisions for
working on identifiable clinical images, and to deliver secure data
sharing among consortium members. It has been constructed to
align with the goals and objectives of the GA4GH.144 The Minerva
Consortium (MC) is an international network of clinicians and
researchers, from both public and private organizations. The public
website Minerva&Me allows anyone around the world to partici-
pate directly in the Minerva Initiative.145 Initiatives such as the Mi-
nerva Initiative are poised to lead the way in terms of not only
amassing data but also using integrative technologies for accessing
and using data at the point of care.
While 3DFA was originally developed for RD diagnostic applica-
tions, it can also be applied to treatment monitoring for both rare
and common diseases, as demonstrated in a new project traversing
specialties at the Perth Children’s Hospital and Western Australia’s
premier clinical trials facility, Linear Clinical Research. In addition,
while 3DFA is yielding translational insights into innovations for di-
agnosis, treatment, and monitoring in the RD domain, it also exam-
ines the overlap between rare and more common diseases and,
therefore, mechanistic research. Notably, population-level studies
demonstrated that common genetic variations (polymorphisms)
were associated with discrete patterns of facial variation. Notably,
these facial signatures recapitulated the characteristic facies of the
respective genetic syndrome due to rare genetic variation (patho-
genic variants).146 An example of a common disease that is poised
for 3D facial translational research is obstructive sleep apnea (OSA).
OSA is a condition seen in RDs such as mucopolysaccharidoses,
where it regularly has an earlier onset than in the general popula-
tion. These findings highlight the overlap between common and rare
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phenotypes, with implications for possible reciprocal (rare-common)
insights.147
Data acquisition, analysis, and sharing mechanisms for identifi-
able facial data are key to RD diagnosis and research, but special-
ized approaches are required to simultaneously facilitate more Open
Science while respecting patient privacy.
Telemedicine
Developments in modern communication technology such as tele-
medicine have created new opportunities for the delivery of health
services to remote areas and unprivileged communities. Telemedi-
cine refers to communication tools for medical care delivery at a dis-
tance, including telephones, smart phones, interactive televideo,
“store-and-forward” images and medical record transmission via
personal computers, and remote monitoring.148 High-speed tele-
communications systems, in addition to the invention of devices ca-
pable of capturing and transmitting images and other data in digital
form, have facilitated better sharing, collaboration, and efficiency in
telemedicine. As a result, health professionals can communicate
faster, more widely, and more directly with other clinicians and
patients regardless of location.
Access to medical care is a major concern for RD patients and
their families not only in rural areas and developing countries.
Among the main issues are a lack of physicians specialized in RD
treatment; concerns about sharing personal information and the se-
curity of personal information, few programs and resources to sup-
port low socioeconomic families with travel accommodation, as
well as loss of income associated with obtaining care from specialists
at long distances.149
RD and undiagnosed patients are usually dispersed over a large
geographical area, yet they require multidisciplinary experts. As a
result, a correct diagnosis may be delayed, and ready access to ongo-
ing care is limited. Thus, telemedicine can profoundly change pa-
tient care for individuals with RD and directly address challenges of
geography, travel burden, and access to experts; it can provide open
access and global data sharing. Telemedicine can increase patient ac-
cess to health care services otherwise unavailable149 as well as for
patients in developing countries and rural/remote area.150 If utilized
to its potential, telemedicine may open the way for more equitable
distribution of knowledge and medical care throughout the
world.149,150 In 2020, the Mayo Clinic plans to serve 200 million
patients, many of them from outside the United State and most of
them remotely.149
Telemedicine can revolutionize the way in which healthcare is
delivered and allow the home to become a preferred place of care.
The advantages of this approach are patient satisfaction, reduced
travel requirements to health care providers, clinics and hospitals,
early intervention for disease progression, support for caregivers,
and economic benefits associated with reduced hospitalization
rates.151
In addition to the increased connectivity between providers and
patients, telemedicine also provides a means for researchers to con-
nect to potential participants. Mobile and wearable medical devices
enable patients to share and transmit a wealth of digital health data
to databases contributing to patient registries, natural history stud-
ies, and clinical trials. Telemedicine has already been used and
proven its value for chronic non-RDs, such as congestive heart fail-
ure and chronic obstructive pulmonary disease152 as well as some
RDs, such as mesothelioma,153,154 cystic fibrosis,155 diabetes,156–159
Prader–Willi syndrome,160 and juvenile idiopathic arthritis.161 As
promising as telemedicine sounds, it cannot be a replacement for in-
person examination. There are significant limitations and barriers
that need to be addressed and overcome, including quality of
patient-clinician interaction, insurance coverage, reimbursement for
services, privacy and legal issues of state licensure laws and liability
concerns.
Providing care through telemedicine technology may not work
for every organization. However, with the move toward personal-
ized medicine, incorporating telemedicine into the health system can
offer benefits to physicians and patients.162 Examples for reductions
in use of services are hospital admissions/re-admissions, length of
hospital stay, and emergency department visits that translate into re-
duced mortality.152 To increase the uses and implementation of tele-
medicine, more resources and studies are needed to evaluate the net
value, visibility, and access for patients and the health care pro-
viders.
Telemedicine can emerge as an important component of the
health care delivery system that relies on sharing medical informa-
tion, knowledge and collaboration, which are the building blocks
necessary to facilitate Open Science. RD patients and their families
seem to more enthusiastically share personal information and col-
laborate because they desperately want to find the correct diagnosis,
experts, and treatment.
In the context of global health, telemedicine is beginning to have
an important impact on many aspects of healthcare, especially in de-
veloping countries and in rural areas, opening the way for distribu-
tion of knowledge and medical care throughout the world.150
Although Open Science can aid the RD community, the RD commu-
nity can be instrumental for Open Science and aid to further the de-
velopment of Open Science by adopting and incorporating
telemedicine and new technologies into health care delivery.
Ethical and legal considerations
We have demonstrated the significant need for Open Science prac-
tice to share data and collaborate in support of RD diagnosis, re-
search, and patient care. Open Science creates some dilemmas and
opposing forces with regards to privacy and ethical concerns. Expe-
rience with the RD patients and their families has demonstrated that
their eagerness for adequate diagnosis and treatment override the
privacy concerns. Nevertheless, as new technologies, and systems
are developed and implemented, the ethical and legal challenges in-
crease.163,164
Global data sharing creates significant challenges for the respon-
sible stewardship of the growing number of large and complex data-
sets, including oversight, accountability, and data management.
Ethical and legal frameworks are required to protect the rights of af-
fected individuals, while still sharing data appropriately to promote
progress in RD research and health care. For example, before in-
creasing the availability and dissemination of RD patient data, scien-
tists must consider participant protections and appropriate data use,
consent, and participant understanding of data sharing, ownership,
reuse, analysis and the generation of new or derived data, among
other concerns.
A number of international organizations165 have devoted consid-
erable attention and resources to developing regulatory frameworks
for open data production, dissemination and use. The frameworks
have resulted in national policies on Open Science, and documents
such as the international accord Open Data in a Big Data World,166
the Open Science policy by the European Commission,167 and the
National Academies of Science “Open Science by Design: Realizing
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a Vision for 21st Century Research”,168 which recommends that
data be made FAIR based on legal and ethical considerations. The
Biobanking and BioMolecular Resources Research Infrastructure-
European Research Infrastructure Consortium (BBMRI ERIC) is
building an international Code of Conduct for health research, with
the aim of contributing to the proper application of the regulation,
taking into account the specific features of processing personal data
in the area of health research in order to clarify and specify certain
rules of the General Data Protection Regulation (GDPR) for those
who process personal data for scientific research in the area of
health.169 Similarly, the NIH Genomic Data Sharing Policy170
includes provisions for the sharing of large-scale genomic data while
taking into account participant protections and limitations on data
use based on the consent of the study participants. All of these
efforts emphasize the importance of good data practices in the shar-
ing, dissemination, and re-use of biomedical data, particularly con-
sidering issues of privacy, confidentiality, intellectual property and
security.165 Clinical trial data sharing has been particularly challeng-
ing when it involves the pharmaceutical industry or other entities
with IP interests. With the extremely small RD cohorts, it is
especially important to coordinate and to share results globally. The
Vivli (https://vivli.org/) program aims to support sharing and reuse
of clinical research data, including individual participant-level data
from completed clinical trials globally. Medical journals generally
require clinical trials to be posted on clinicaltrials.gov, and FDAAA
requirements include submission of the data of both positive and
negative studies. However, for RDs, it is especially important to
share trial information as trials are being designed and launched, so
that different studies can be aligned and patients can be recruited
from around the world. PAGs for each RD have been successful in
doing so, and approaches such as those attempted in OpenTrials
(https://opentrials.net/) are laudatory but are not yet established
enough to support the RD community.
Approaching ethical challenges from an international standpoint
is central to the promise of Open Science.171
Addressing Indigenous rights and interests in genomic and other
data sharing is critical for equitable scientific translation. While In-
digenous experiences with genetic research have been shaped by a
series of negative interactions, there is increasing recognition that
equitable benefits can only be realized through greater participation
of Indigenous communities. Issues of trust, accountability, return of
benefit and equity will need to be addressed. In this context, it is no-
table that the Research Data Alliance International Indigenous Data
Sovereignty Interest Group172 developed the CARE Principles for In-
digenous Data Governance. These principles identify Collective ben-
efit, Authority to control, Responsibility, and Ethics to be used
alongside other data centric principles.
While critically important and relevant to all health care domains,
endeavors such as these do not specifically take into account the spe-
cial Open Science needs of RD patients and caregivers. RD advocacy
and methods for robust and informed data sharing must be developed
alongside policies and secure infrastructure that are specifically
designed for sharing data about RD patients—who by their very rarity
have a much greater likelihood of re-identification or even a desire to
share identified data. Toward the end of supporting genomic health
ethics for all types of genetic diseases, the GA4GH has created a
“Framework for Responsible Sharing of Genomic and Health-Related
Data”. It contains foundational principles and core elements for re-
sponsible data sharing and is guided by concern for human rights, in-
cluding the right to benefit from the progress of science, as well as
privacy, non-discrimination, and procedural fairness. This is pivotal
for RD patients, since traditional medical privacy laws around the
world may not adequately support the Open Science strategies that
RD diagnosis and research necessitates.
The best practices and ethical-legal considerations for FAIR data
sharing in the context of RDs are still evolving. A necessary im-
provement in the management of data in a FAIR-er direction is the
annotation of patient data with Ethical Legal Social Issue (ELSI)
requirements and choices as determined at the time of collection.
This could constitute a great addition to the quality of data that
could be transferred along with the data itself. This means that if a
certain dataset was collected under the condition of a specific use
(eg, cancer research only in Europe) this information should travel
with the data, ensuring sustainable and ELSI reusability of the data.
While the promises of the Open Science paradigm and the FAIRifi-
cation of data are key to effective research, especially in RD, compli-
ance with existing regulatory requirements and ethical norms is
necessary to ensure long-term sustainability of data stewardship.
New perspectives, understanding and challenges introduced by
rapidly developing machine learning approaches increase the neces-
sity of open data sharing to realize the public good, but simulta-
neously can give rise to new ethical and legal dilemmas. Among the
challenges already becoming apparent are the potential risks for re-
identification, incidental/secondary findings, and biases for equita-
ble access to algorithmically assisted decision making. Particularly
in the context of RD, implications of new machine learning will in-
fluence the best practices and acceptable frameworks for FAIR data
sharing in the coming years.
A ROADMAP FOR OPEN SCIENCE IN RARE
DISEASES
To accelerate the diagnosis and care of RD patients, we propose a
set of recommendations to advance Open Science:
1. Create shared RD definitions, models, and governance.
2. Consider how to realize the FAIR principles in all aspects of the
RD data lifecycle for any given RD, clinical system, or research
initiative.
3. Create metrics for successful compliance with RD-GO FAIR.
4. Support RD tools that enable patients to share their own data
in a well-informed manner and establish standards for consis-
tent representation of phenotype data (eg, Phenopackets and
HPO) as well as genotype and pedigree data.
5. Adopt new standards for registries to support interoperability
and data sharing internationally.
6. Develop methods to create “proxy” data to share representa-
tions or subsets of personally identifiable data (such as facial
images) in a deidentified manner.
7. Establish networks of controlled-access data that can be
searched using diagnostic algorithms for research on RDs.
8. Increase centers specializing in RDs, train more clinicians in di-
agnosing and treating RDs, and create improved clinical
decision-making guidelines related to RDs.
9. Create opportunities for patients to be better informed and en-
courage patient engagement with the scientific community to
increase openness and data sharing.
10. Welcome and attribute openly-developed novel technologies
and interventions in RD clinical settings.
A fundamental component of addressing the RD public health
challenge involves improvements in ethical Open Science, whose
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core principles are data sharing and collaboration. RD families and
their advocates, as well as RD physicians and scientists, have led the
way toward openness, data sharing, and collaboration to find diag-
noses, treatments, and improved quality of life. Despite privacy con-
cerns, institutional policies, and technological barriers, the RD
community has demonstrated that they are thought leaders in Open
Science, forging the way forward for the world.
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